Therapeutic antitumor combination of a TLR4 ligand with other treatments
US11266746B2 · kind B2 · utility
0Cited by
3References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 24, 2017 |
| Grant date | Mar 8, 2022 |
| Priority date | — |
| Expiry date | Jan 8, 2038 |
Classification
- Technology area (CPC B)Performing Operations; Transporting
- CPC primaryB82Y5/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of treating cancer or reducing the incidence of relapse of a cancer in a subject comprising co-administration of Toll-like receptor (TLR) 4 ligand, such as an HMGN1 protein, and a TLR 7 or 8 ligand, and optionally an immune checkpoint inhibitor, to the subject in need of such therapy. The TLR4-mediated immune-stimulating effect is synergistically enhanced by ligands of TLR7 or 8, and the immune checkpoint inhibitor. Also described here is a nanoparticle delivery platform for the co-administration of the TLR 4 ligand and the TLR 7 or 8 ligand.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.